Skip Navigation

Interventional, Randomized, Double-Blind, Active-Controlled Study of the Efficacy of Lu AF35700 in Patients with Early-in-Disease or Late-in-Disease Treatment-Resistant Schizophrenia

Principal Investigator: Dr. Robert Cotes

Criteria: We are looking to recruit patients who meet the following key criteria:

  • 18 years of age or older
  • confirmed diagnosis of schizophrenia for ≤5 years or ≥10 years
  • demonstrated failure to adequately respond to prior antipsychotics in at least one documented treatment trial with an adequate dose prescribed for at least 6 weeks, in the past 2 years
  • currently treated with antipsychotics for at least 2 weeks. 

Purpose: This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS). Eligible patients will be randomized at some point in the trial to receive either the investigational medication or treatment with either risperidone or olanzapine at an adequate and tolerable dose established during the study. The study will last for approximately 23 weeks.

Compensation: $85 for each study visit 

Contact: Ayesha Khan (Study Coordinator)
Phone: 404-616-0853
Email: akhan31@emory.edu 

Website link: https://clinicaltrials.gov/ct2/show/NCT03230864